News from the healthcare data industry
New studies demonstrate the ability of Foundation Medicine’s portfolio of tests to improve treatment options for patients, and reinforce the company’s role as an essential partner to researchers April 05,...
BOSTON, April 5, 2022 /PRNewswire/ — Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), and AstraZeneca have published results from their ZEPHYR 1 study, the first real-world...
Cambridge, MA, April 4, 2022 — TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of new therapies, enabled researchers at Hospital Universitario 12 de Octubre...
Analysis Suggests Use of RADICAVA IV is Associated with Improved Survival in People with ALS JERSEY CITY, N.J., April 4, 2022 /PRNewswire/ — Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the...
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosing Additional real-world data affirm...
By Chuck Dinerstein, MD, MBA — April 1, 2022Pneumonia is a relatively common problem resulting in antibiotics and the need, in some cases, for hospitalization or intensive care. Can physicians follow guidelines...
Data being presented at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference March 31, 2022 16:05 ET | Source: G1 Therapeutics RESEARCH TRIANGLE PARK, N.C., March 31, 2022 (GLOBE NEWSWIRE) —...
DURHAM, N.C., March 29, 2022 /PRNewswire/ — New real-world data evaluating alanine aminotransferase (ALT) in children uncovered disparities in prevalence and severity of non-alcoholic fatty liver disease (NAFLD). The study, Variation in Alanine...
DURHAM, N.C., March 29, 2022 /PRNewswire/ — New real-world data evaluating alanine aminotransferase (ALT) in children uncovered disparities in prevalence and severity of non-alcoholic fatty liver disease (NAFLD). The study, Variation in Alanine...
Researchers open new opportunities to address liver disease. PALO ALTO, Calif., March 24, 2022 /PRNewswire/ — Verantos, the market leader in high-validity real-world evidence generation, announced that along with its research partners, the...